Nevirapine Pharmacokinetics in Neonates Between 25 and 32 Weeks Gestational Age for the Prevention of Mother-to-Child Transmission of HIV

Supplemental Digital Content is available in the text. Eleven newborns from 25 to 32 weeks of gestational age, weighting from 0.66 to 1.60 kg received 2 mg/kg doses of nevirapine syrup. In 15 samples, collected 8.75–89 hours after drug intake, concentrations ranged from 0.65 to 16.68 mg/L. Three nevirapine dose of 2 mg/kg at day 0, 2 and 6 days of life achieved nevirapine concentrations above the proposed nevirapine target for HIV prophylaxis for at least 11 days.

• Publication year

  2021

• Venue

  The Pediatric Infectious Disease Journal

• Publication date

  2021-03-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/INF.0000000000002994PMID 33710978
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nevirapine Pharmacokinetics and Safety in Neonates Receiving Combination Antiretroviral Therapy for Prevention of Vertical HIV Transmission

  2017cited by this paper
• Nevirapine Concentrations in Preterm and Low Birth Weight HIV-Exposed Infants: Implications for Dosing Recommendations

  2014influential reference
• Neurodevelopment and In Utero Antiretroviral Exposure of HIV-Exposed Uninfected Infants

  2010cited by this paper
• [Possible long-term effect of in utero antiretroviral exposure?].

  2007cited by this paper
• Possible effet à long terme de l'exposition in utero aux antirétroviraux ?

  2007cited by this paper
• Mitochondrial dysfunction following perinatal exposure to nucleoside analogues

  2006cited by this paper
• Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs.

  2004cited by this paper

• Management Strategies in Perinatal HIV

  2023cites this paper